Press Releases

Press Releases 2010
Press Releases 2009
Press Releases 2008
Press Releases 2007
Press Releases 2006
Press Releases 2005
Press Releases 2004
Press Releases 2003

Press Releases

If you wish to be informed regularly about MediGene's press releases, you can subscribe to our investor's newsletter.

MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties

2010-07-19

MediGene reports additional phase II results of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer

2010-06-24

MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea

2010-05-10

MediGene AG reports on first quarter of 2010: total revenue increased – cost constant

2010-05-07

MediGene publishes first, preliminary results obtained in a phase II clinical trial of EndoTAG(TM)-1 for the treatment of triple receptor-negative breast cancer

2010-05-06

New CFO Arnd Christ to take up position at MediGene in April

2010-04-19

MediGene AG divests Oncolytic Herpes Simplex Viruses (oHSV) program to Catherex, Inc.

2010-04-13

MediGene Signs Agreement with Meditrina for the Commercialization of Veregen® in Greece and Cyprus

2010-04-01

MediGene appoints Arnd Christ as Chief Financial Officer as Successor to Dr. Thomas Klaue

2010-03-26

MediGene AG Reports Financial Results for the 2009 Fiscal Year

2010-03-26

MediGene’s Veregen® launched by Solvay in Germany

2010-03-01

MediGene and Teva sign agreement to commercialize Veregen™ in Israel

2010-02-22

Für weitere Informationen wenden Sie sich bitte an Dr. Georg Dönges oder Julia Hofmann, Public Relations, MediGene AG

Kontakt